Merck & Co.
AWARDS
NEWS
Powered by its blockbuster checkpoint inhibitor Keytruda, Merck is forecasting a potential of more than 80 new regulatory approvals in oncology through 2028.
The results demonstrated that Jardiance reduced the risk of hospitalization for heart failure compared to two other classes of glucose-lowering drugs in adults with type 2 diabetes.
In the next eight years, more than 190 drugs will go off-patent for these companies. Of those, 69 are blockbuster drugs. ZS Associates’ Maria Whitman provides analyses and tips.
Pharma giant Merck announced it is expanding in both area and headcount with a new Cambridge, MA office. The company’s plan is to add 160,000 square feet and 100 new employees.
U.K. researchers found that the first dose of any vaccine was linked with an initial 12.8% decrease in the odds of Long COVID.
Possibly reflecting the current Bear market, Berkshire Hathaway has walked away from its stake in both AbbVie and BMS.
JOBS
IN THE PRESS